Theravance Biopharma, Inc. (TBPH) DCF Valuation

Theravance Biopharma, Inc. (TBPH) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Theravance Biopharma, Inc. (TBPH) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our (TBPH) DCF Calculator enables you to evaluate Theravance Biopharma, Inc. valuation using real-world financial data and complete flexibility to modify all key parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 73.4 71.9 55.3 51.3 57.4 54.5 51.7 49.0 46.5 44.2
Revenue Growth, % 0 -2.12 -23.03 -7.17 11.84 -5.12 -5.12 -5.12 -5.12 -5.12
EBITDA -203.3 -294.0 -249.4 -79.9 -40.9 -51.3 -48.7 -46.2 -43.9 -41.6
EBITDA, % -276.91 -409.14 -450.88 -155.53 -71.17 -94.23 -94.23 -94.23 -94.23 -94.23
Depreciation 6.5 6.6 7.3 6.6 6.1 6.0 5.7 5.4 5.1 4.8
Depreciation, % 8.89 9.25 13.17 12.83 10.54 10.94 10.94 10.94 10.94 10.94
EBIT -209.8 -300.6 -256.7 -86.4 -46.9 -52.5 -49.8 -47.3 -44.8 -42.5
EBIT, % -285.8 -418.39 -464.06 -168.36 -81.71 -96.34 -96.34 -96.34 -96.34 -96.34
Total Cash 280.8 292.9 173.5 327.5 102.4 54.5 51.7 49.0 46.5 44.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 69.7 57.6 16.8 17.5
Account Receivables, % 0 96.95 104.14 32.69 30.43
Inventories .0 20.4 10.2 1.5 .0 5.4 5.2 4.9 4.6 4.4
Inventories, % 0.000001362138 28.35 18.52 2.95 0 9.96 9.96 9.96 9.96 9.96
Accounts Payable 4.8 6.8 3.1 1.6 1.5 3.0 2.8 2.7 2.5 2.4
Accounts Payable, % 6.48 9.43 5.6 3.03 2.65 5.44 5.44 5.44 5.44 5.44
Capital Expenditure -3.2 -6.6 -3.4 -.6 -2.5 -2.7 -2.6 -2.5 -2.3 -2.2
Capital Expenditure, % -4.33 -9.21 -6.16 -1.11 -4.33 -5.03 -5.03 -5.03 -5.03 -5.03
Tax Rate, % -12.02 -12.02 -12.02 -12.02 -12.02 -12.02 -12.02 -12.02 -12.02 -12.02
EBITAT -205.3 -291.7 -256.5 -86.5 -52.6 -51.9 -49.3 -46.8 -44.4 -42.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -197.2 -379.7 -234.1 -32.4 -48.2 -63.6 -44.7 -42.4 -40.2 -38.1
WACC, % 5.55 5.55 5.56 5.56 5.56 5.56 5.56 5.56 5.56 5.56
PV UFCF
SUM PV UFCF -197.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -39
Terminal Value -1,093
Present Terminal Value -834
Enterprise Value -1,032
Net Debt 10
Equity Value -1,042
Diluted Shares Outstanding, MM 55
Equity Value Per Share -18.84

What You Will Get

  • Real Theravance Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Theravance Biopharma, Inc. (TBPH).
  • Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
  • Instant Valuation Updates: Automatic recalculations to assess the impact of changes on Theravance’s fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections tailored to Theravance Biopharma, Inc. (TBPH).
  • Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility in your evaluations.

Key Features

  • Real-Time TBPH Data: Pre-filled with Theravance Biopharma’s historical financials and future growth projections.
  • Fully Customizable Inputs: Modify revenue growth rates, profit margins, discount rates, tax obligations, and capital investments.
  • Dynamic Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your specified inputs.
  • Scenario Analysis: Develop various forecast scenarios to evaluate different valuation results.
  • User-Friendly Interface: Intuitive, organized, and suitable for both experts and newcomers.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Theravance Biopharma data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Theravance Biopharma’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Theravance Biopharma, Inc. (TBPH)?

  • Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for biotech firms.
  • Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
  • Detailed Insights: Automatically computes Theravance’s intrinsic value and Net Present Value.
  • Preloaded Data: Access to historical and projected data for precise analysis.
  • Professional Quality: Perfect for financial analysts, investors, and biotech consultants.

Who Should Use This Product?

  • Investors: Evaluate Theravance Biopharma’s valuation before making stock trades.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
  • Startup Founders: Discover how large biotech firms like Theravance Biopharma are appraised.
  • Consultants: Provide comprehensive valuation reports for clients in the biotech sector.
  • Students and Educators: Utilize real-time data to practice and instruct on valuation strategies.

What the Template Contains

  • Pre-Filled Data: Includes Theravance Biopharma's historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Theravance Biopharma's profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.